The UK government has announced significant new funding to support pioneering life sciences projects, aiming to transform healthcare, enhance economic growth, and strengthen national renewal. This investment will back bold initiatives ranging from the use of robots in medicine production to turning spent nuclear fuel into innovative cancer therapies. It forms a key part of the Industrial Strategy, recognising the £100 billion life sciences sector as central to the country’s health, economic, and scientific ambitions.
Through more than £74 million in combined government and industry funding, eight innovative R&D projects under the Sustainable Medicines Manufacturing Innovation Programme will receive support. These projects aim to make medicines production more efficient and environmentally sustainable, including recycling anaesthetic gases, developing low-waste manufacturing systems, and employing AI and robotics in pharmaceutical factories. The initiative is delivered by Innovate UK and further supplemented by over £20 million in industry backing.
In parallel, the Medicines and Healthcare products Regulatory Agency (MHRA) will receive nearly £1 million from the Engineering Biology Sandbox Fund to address regulatory challenges around engineered bacteriophage products. These specially-designed viruses could tackle the growing threat of antibiotic-resistant bacteria, ensuring that innovation in this area progresses safely and effectively while maintaining public confidence.
Government officials highlighted the importance of this support for the UK’s life sciences sector. Science and Technology Secretary Liz Kendall noted the sector’s contribution of £150 billion in annual turnover and hundreds of thousands of jobs, while Business and Trade Secretary Peter Kyle emphasised the UK’s ambition to become a life sciences superpower. Health and Innovation Minister Dr Zubir Ahmed highlighted the sector’s potential to advance treatments for cancer and antimicrobial resistance, combining scientific ingenuity with the NHS’s capabilities.
The funding also coincides with London Life Sciences Week, bringing together investors, researchers, policymakers, and industry leaders to drive collaboration and investment. Notable initiatives include the British Business Bank’s €30 million commitment to Sofinnova Capital XI, a pan-European venture capital fund, and Barts Health NHS Trust’s £800 million Barts Life Sciences Cluster, designed to attract private and academic investment into the capital.
The UK life sciences sector remains a key economic driver, employing over 300,000 people and attracting significant venture capital. Recent investments include BioNTech’s £1 billion programme, Wellcome-backed £600 million Health Data Research Service, Moderna’s Innovation and Technology Centre, and GSK-Oxford Cancer Immuno-Prevention Programme funding, underlining the sector’s global leadership in biopharmaceutical and medical technology innovation.
Projects funded under the Sustainable Medicines Manufacturing Innovation Programme exemplify the focus on sustainable, cutting-edge solutions. Initiatives include developing circular pharmaceutical packaging, digital biocatalysis, environmentally-friendly peptide production, sustainable CAR-T cell manufacturing, integrated photonics for higher process efficiency, converting nuclear material into cancer therapies, optimizing anaesthetic gas reuse, and creating AI-driven future-ready medicine factories. These projects aim to reduce waste, improve efficiency, and accelerate the UK’s transition to sustainable, technologically advanced medicines manufacturing.
